Treatment with a β-blocker with β2-agonism improves glucose and lipid metabolism in essential hypertension
- 30 April 1994
- journal article
- clinical trial
- Published by Elsevier in Metabolism
- Vol. 43 (4) , 455-461
- https://doi.org/10.1016/0026-0495(94)90076-0
Abstract
No abstract availableKeywords
Funding Information
- Medicinska Forskningsrådet (5446)
- Schering-Plough
This publication has 47 references indexed in Scilit:
- CeliprololDrugs, 1991
- DilevalolDrugs, 1990
- A Comparison of the Effects of Hydrochlorothiazide and Captopril on Glucose and Lipid Metabolism in Patients with HypertensionNew England Journal of Medicine, 1989
- Clinical Pharmacology of Dilevalol (II). The Pharmacokinetic, Pharmacodynamic, and Tolerance Studies of Dilevalol During Repeated Administration in Healthy SubjectsThe Journal of Clinical Pharmacology, 1989
- A long-term study of the effects of celiprolol on blood pressure and lipid-associated risk factorsAmerican Heart Journal, 1988
- Captopril enhances insulin responsiveness of forearm muscle tissue in non‐insulin‐dependent diabetes mellitusEuropean Journal of Clinical Investigation, 1987
- Insulin Resistance in Essential HypertensionNew England Journal of Medicine, 1987
- Hemodynamic Effects at Rest and during Exercise in Long‐term Treatment with Prazosin in Chronic Congestive Heart FailureActa Medica Scandinavica, 1986
- Metabolic disturbances increasing the risk of coronary heart disease during diuretic-based antihypertensive therapy: Lipid alterations and glucose intoleranceAmerican Heart Journal, 1983
- Terbutaline Raises High-Density-Lipoprotein-Cholesterol LevelsNew England Journal of Medicine, 1981